Building E, 7th Floor, Room E7.6
30 articles about Confo Therapeutics
Confo Therapeutics Reports Grant of Two Key Patents for ConfoBodies™
Confo Therapeutics, a pioneering biopharma company, announces that it has been granted two key ConfoBodyTM patents derived from the patent estate known as the “Steyaert patents”.
Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds
Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH announce a drug discovery collaboration on an undisclosed G-protein coupled receptor.
Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication
Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO).
Confo Therapeutics Raises €30 Million in Series A Financing
Round led by BioGeneration Ventures and co-led by Wellington Partners, with investments by Fund+, Perceptive Advisors and existing investors
BioSpace Movers and Shakers: March 1
3/1/2019Pharma and biotech companies make changes to leadership roles, with new hires at Agios, Notable, Rapamycin, Confo, AVEO and more.
Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology
Confo Therapeutics today announces that it has entered into an agreement with VIB, a life sciences research institute in Flanders, Belgium, for an exclusive, worldwide license to VIB’s ‘Megabody’ technology.
BioSpace Movers and Shakers for Dec. 10
12/10/2018Biotech and pharma companies strengthen their leadership teams with these appointments. Who made power moves in the industry this past week?
Confo Therapeutics Appoints Frank Landolt as its Chief Counsel Legal & Intellectual Property
Confo Therapeutics today announces the appointment of Frank Landolt as its Chief Counsel Legal & IP, effective from 1 January 2019.
Confo Therapeutics announced today that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed GPCR for the treatment of neurological and developmental disorders.
Confo Therapeutics Secures €6.7 Million In First Financing Round